(0.74%) 5 120.00 points
(0.15%) 38 344 points
(0.98%) 17 740 points
(1.04%) $84.44
(-6.59%) $1.530
(0.54%) $2 355.20
(0.74%) $27.56
(0.34%) $923.60
(0.13%) $0.933
(0.55%) $11.01
(0.03%) $0.800
(-0.23%) $91.96
Live Chart Being Loaded With Signals
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial...
Stats | |
---|---|
Today's Volume | 55 650.00 |
Average Volume | 146 418 |
Market Cap | 217.29M |
EPS | $0 ( 2024-02-25 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -18.71 |
ATR14 | $0.0130 (0.99%) |
Race Oncology Ltd Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Race Oncology Ltd Financials
Annual | 2023 |
Revenue: | $3.13M |
Gross Profit: | $2.85M (91.03 %) |
EPS: | $-0.0617 |
FY | 2023 |
Revenue: | $3.13M |
Gross Profit: | $2.85M (91.03 %) |
EPS: | $-0.0617 |
FY | 2022 |
Revenue: | $707 807 |
Gross Profit: | $426 611 (60.27 %) |
EPS: | $-0.0731 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.0794 |
Financial Reports:
No articles found.
Race Oncology Ltd
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators